IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
-4.43%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$307M
AUM Growth
+$307M
(-12%)
Cap. Flow
+$18.2M
Cap. Flow
% of AUM
5.93%
Top 10 Holdings %
Top 10 Hldgs %
39.15%
Holding
181
New
26
Increased
23
Reduced
31
Closed
32
Top Buys
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
$14M |
| 2 |
Akero Therapeutics
AKRO
|
$9.92M |
| 3 |
Sarepta Therapeutics
SRPT
|
$8.62M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$8.53M |
| 5 |
Vaxcyte
PCVX
|
$7.55M |
Top Sells
| 1 |
Spyre Therapeutics
SYRE
|
$6.57M |
| 2 |
Tarsus Pharmaceuticals
TARS
|
$6.3M |
| 3 |
Avalo Therapeutics
AVTX
|
$6.17M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
$4.91M |
| 5 |
BridgeBio Pharma
BBIO
|
$4.32M |
Sector Composition
| 1 | Healthcare | 95.44% |
| 2 | Consumer Staples | 0% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Kezar Life Sciences
KZR
$28.5M
| $522K | 0.06% |
106,901
| – | – |
|
77
BiomX
PHGE
$14.1M
| $496K | 0.06% |
892,976
| – | – |
|
78
Lyell Immunopharma
LYEL
$220M
| $471K | 0.06% |
876,037
-400,000
| -31% | -$215K |
|
|
ITOS
79
DELISTED
iTeos Therapeutics
ITOS
| $469K | 0.06% |
78,585
| – | – |
|
|
VIGL
80
DELISTED
Vigil Neuroscience
VIGL
| $445K | 0.05% |
250,000
-250,000
| -50% | -$445K |
|
81
Aethlon Medical
AEMD
$3.51M
| $440K | 0.05% |
1,229,285
+479,285
| +64% | +$172K |
|
82
Alto Neuroscience
ANRO
$97.7M
| $378K | 0.05% |
175,000
-175,000
| -50% | -$378K |
|
83
MindMed
MNMD
$689M
| $367K | 0.05% |
62,691
| – | – |
|
|
THRD
84
DELISTED
Third Harmonic Bio
THRD
| $347K | 0.04% |
100,000
| – | – |
|
85
Ginkgo Bioworks
DNA
$671M
| $332K | 0.04% |
+58,300
| New | +$332K |
|
86
Tyra Biosciences
TYRA
$657M
| $326K | 0.04% |
35,000
-25,000
| -42% | -$233K |
|
87
Acumen Pharmaceuticals
ABOS
$84.2M
| $292K | 0.04% |
265,769
| – | – |
|
88
Cartesian Therapeutics
RNAC
$267M
| $292K | 0.04% |
22,166
-30,000
| -58% | -$395K |
|
|
SPRB
89
DELISTED
Spruce Biosciences, Inc. Common Stock
SPRB
| $290K | 0.04% |
1,000,000
| – | – |
|
|
ALLK
90
DELISTED
Allakos
ALLK
| $267K | 0.03% |
1,171,950
+200,000
| +21% | +$45.5K |
|
91
Geron
GERN
$893M
| $239K | 0.03% |
+150,000
| New | +$239K |
|
|
CMMB
92
Chemomab Therapeutics
CMMB
$15.7M
| $232K | 0.03% |
213,052
| – | – |
|
93
Aclaris Therapeutics
ACRS
$223M
| $231K | 0.03% |
150,900
-199,100
| -57% | -$305K |
|
94
Monopar Therapeutics
MNPR
$223M
| $215K | 0.03% |
5,908
| – | – |
|
|
CLYM
95
Climb Bio, Inc. Common Stock
CLYM
$165M
| $214K | 0.03% |
175,088
| – | – |
|
96
PepGen
PEPG
$39M
| $211K | 0.03% |
+150,000
| New | +$211K |
|
97
Anebulo Pharmaceuticals
ANEB
$101M
| $205K | 0.03% |
157,720
| – | – |
|
98
Voyager Therapeutics
VYGR
$204M
| $188K | 0.02% |
55,766
| – | – |
|
|
ELEV
99
DELISTED
Elevation Oncology
ELEV
| $179K | 0.02% |
690,050
| – | – |
|
100
Sensei Biotherapeutics
SNSE
$10.9M
| $177K | 0.02% |
449,963
-200,000
| -31% | -$78.8K |
|